Isonid 300 mg
Isoniazid
Category: Tablet
Manufacturer: G. A. Company Ltd.
Allopathic
MFG. Licence No. Biological
024
MFG. Licence No. Non-Biological
102
Address
Tejgaon I/A, Dhaka
Medicine Selling service is not available yet.
Uses of Isonid:
- Tuberculosis (TB)
Tuberculosis
Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.
How to use
Isoniazid:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Isoniazid is to be taken empty stomach.
Avoid
Isoniazid with tyramine-rich food such as cheese, smoked fish, meats and some types of beer.
Administration:
Should be taken on an empty stomach. Best taken on an empty stomach 1 hr before or 2 hr after meals. May be taken w/ meals to reduce GI discomfort.
Adult Dose:
Oral
Active Tuberculosis Disease
5 mg/kg PO qDay, not to exceed 300 mg qDay
15 mg/kg PO up; not to exceed 900 mg 1-3 times/week
Used in multi-drug regimen containing rifampin (or ribabutin or rifapentin), pyrazinamide, and ethambutol
Latent Tuberculosis Infection
Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease
>30 kg: 300 mg PO qDay x9 months
Child Dose:
Active Tuberculosis Disease
10-15 mg/kg PO qDay; not to exceed 300 mg/day OR
20-30 mg/kg (up to 900 mg) 2 times/week
Used in multi-drug regimen
Latent Tuberculosis Infection
Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease
10-15 mg/kg PO qDay; not to exceed 300 mg/day
Renal Dose:
Renal impairment: Severe: Dose reduction may be needed.
Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.
Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.
Common
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Increased liver enzymes
- Hepatitis (viral infection of liver)
- Jaundice
>10%
Mild incr LFTs (10-20%),Peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d)
Loss of appetite,Nausea,Vomiting,Stomach pain,Weakness
1-10%
Dizziness,Slurred speech,Lethargy,Progressive liver damage (increases with age; 2.3% in pts > 50 yo),Hyperreflexia
<1%
Agranulocytosis,Anemia,Megaloblastic anemia,Thrombocytopenia,Systemic lupus erythematosus,Seizure
Potentially Fatal: Hepatotoxicity.
Precaution:
Renal or hepatic impairment; convulsive disorders; history of psychosis; patients at risk of neuropathy or pyridoxine deficiency eg, diabetic, alcoholic, malnourished, uraemic, infected with HIV. Careful monitoring of hepatic function is necessary for black and hispanic women. Check hepatic function before and during treatment. Pregnancy and lactation.
Lactation: distributed into milk but safe for nursing infants
Anti-Tubercular Chemotherapeutics
Isoniazid inhibits the synthesis of mycoloic acids in susceptible bacteria which results in loss of acid-fastness and disruption of bacterial cell wall. At therapeutic levels, it is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms.
Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksLactation: distributed into milk but safe for nursing infants
Samm Care